XML 67 R49.htm IDEA: XBRL DOCUMENT
v3.22.1

Stockholders' Equity (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2022
Stockholders' Equity Note [Abstract] |
Schedule of shares repurchased over last three years | Information regarding share repurchase activity over the last three years is as follows:
| Share Repurchases (1)
(In millions, except price per share data) |  | Total Number of Shares Purchased (2) |  | Average Price Paid Per Share |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs
Balance, March 31, 2019 |  |  |  |  |  | $ | 3,469 |
Shares repurchased - Open market |  | 9.2 |  |  | $ | 144.68 |  |  | (1,334) |
Shares repurchased - May 2019 ASR |  | 4.7 |  |  | $ | 127.68 |  |  | (600) |
Balance, March 31, 2020 |  |  |  |  |  | 1,535 |
Shares repurchase authorization increase in 2021 |  |  |  |  |  | 2,000 |
Shares repurchased - Open market (3) |  | 4.7 |  |  | $ | 160.33 |  |  | (750) |
Balance, March 31, 2021 |  |  |  |  |  | 2,785 |
Shares repurchased - May 2021 ASR |  | 5.2 |  |  | $ | 193.22 |  |  | (1,000) |
Shares repurchased - Open market |  | 4.6 |  |  | $ | 217.73 |  |  | (1,007) |
Shares repurchase authorization increase in 2022 |  |  |  |  |  | 4,000 |
Shares repurchased - February 2022 ASR (4) |  | 4.8 |  |  | $ | 265.56 |  |  | (1,500) |
Balance, March 31, 2022 |  |  |  |  |  | $ | 3,278 |
(1)This table does not include the value of equity awards surrendered to satisfy tax withholding obligations or forfeitures of equity awards. It also excludes shares related to the Company’s Split-off of the Change Healthcare JV as described below. (2)The number of shares purchased reflects rounding adjustments. (3)Of the total dollar value, $8 million was accrued within “Other accrued liabilities” in the Company’s Consolidated Balance Sheet as of March 31, 2021 for share repurchases that were executed in late March and settled in early April. (4)In February 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.5 billion of the Company’s common stock. The average price paid per share and total number of shares purchased under this program are estimates based on the initial share purchase price and initial delivery of shares under an ASR agreement and may differ from the average price paid per share and total number of shares purchased under the ASR program upon its final settlement in May 2022.
Schedule of accumulated other comprehensive income (loss) | Information regarding changes in the Company’s accumulated other comprehensive income (loss) by component are as follows:
| Foreign Currency Translation Adjustments |  |  |  |  |  |
(In millions) | Foreign Currency Translation Adjustments, Net of Tax (1) |  | Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax (2) |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  | Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax |  | Total Accumulated Other Comprehensive Loss
Balance at March 31, 2019 | $ | (1,628) |  |  | $ | 53 |  |  | $ | (37) |  |  | $ | (237) |  |  | $ | (1,849) |
Other comprehensive income (loss) before reclassifications | (151) |  |  | 85 |  |  | 86 |  |  | 33 |  |  | 53 |
Amounts reclassified to earnings and other (3) | — |  |  | — |  |  | — |  |  | 96 |  |  | 96 |
Other comprehensive income (loss) | (151) |  |  | 85 |  |  | 86 |  |  | 129 |  | 149 |
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests | 1 |  |  | — |  |  | — |  |  | 2 |  |  | 3 |
Other comprehensive income (loss) attributable to McKesson | (152) |  |  | 85 |  |  | 86 |  |  | 127 |  | 146 |
Balance at March 31, 2020 | (1,780) |  |  | 138 |  |  | 49 |  |  | (110) |  |  | (1,703) |
Other comprehensive income (loss) before reclassifications | 312 |  |  | (175) |  |  | (36) |  |  | (2) |  |  | 99 |
Amounts reclassified to earnings and other (4) | 47 |  |  | — |  |  | — |  |  | 24 |  |  | 71 |
Other comprehensive income (loss) | 359 |  |  | (175) |  |  | (36) |  |  | 22 |  |  | 170 |
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests | (60) |  |  | (1) |  |  | — |  |  | 8 |  | (53) |
Other comprehensive income (loss) attributable to McKesson | 419 |  |  | (174) |  |  | (36) |  |  | 14 |  | 223 |
Balance at March 31, 2021 | (1,361) |  |  | (36) |  |  | 13 |  |  | (96) |  |  | (1,480) |
Other comprehensive income (loss) before reclassifications | (51) |  |  | 41 |  | 18 |  | 31 |  | 39 |
Amounts reclassified to earnings and other (5) | 71 |  |  | (1) |  |  | (4) |  |  | 10 |  | 76 |
Other comprehensive income | 20 |  |  | 40 |  | 14 |  | 41 |  | 115 |
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests | 5 |  |  | (6) |  |  | — |  |  | — |  |  | (1) |
Other comprehensive income attributable to McKesson | 15 |  | 46 |  | 14 |  | 41 |  | 116 |
Exercise of put right by noncontrolling shareholders of McKesson Europe AG | (158) |  |  | — |  |  | — |  |  | (12) |  |  | (170) |
Balance at March 31, 2022 | $ | (1,504) |  |  | $ | 10 |  |  | $ | 27 |  |  | $ | (67) |  |  | $ | (1,534) |
(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Europe and Canada into the Company’s reporting currency, U.S. dollars. (2)Amounts before reclassifications recorded in 2022, 2021, and 2020 include gains (losses) of $73 million, $(118) million, and $39 million, respectively, related to net investment hedges from Euro-denominated notes and gains (losses) of $(4) million, $(119) million, and $76 million, respectively, related to net investment hedges from cross-currency swaps. These amounts are net of income tax benefit (expense) of $(23) million, $62 million, and $(30) million in 2022, 2021, and 2020, respectively. (3)Primarily reflects a reclassification of losses of $127 million, net of $33 million of income tax benefit, predominantly on the termination of the Company’s U.S. defined benefit pension plan from “Accumulated other comprehensive loss” to “Other income, net” in the Company’s Consolidated Statement of Operations. (4)Primarily includes adjustments for amounts related to the contribution of the Company’s German pharmaceutical wholesale business to a joint venture, as discussed in more detail in Financial Note 2, “Held for Sale” and Financial Note 6, “Other Income, Net.” These amounts were included in the 2021 and 2020 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within Selling, distribution, general, and administrative expenses in the Consolidated Statements of Operations. (5)Primarily includes adjustments for amounts related to the sale of the Company’s Austrian business, as discussed in more detail in Financial Note 2, “Held for Sale.” These amounts were included in the 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within Selling, distribution, general, and administrative expenses in the Consolidated Statement of Operations.

X
- Definition Tabular disclosure of accelerated share repurchase (ASR) programs. An ASR is a combination of transactions that permits an entity to purchase a targeted number of shares immediately with the final purchase price of those shares determined by an average market price over a fixed period of time. An accelerated share repurchase program is intended to combine the immediate share retirement benefits of a tender offer with the market impact and pricing benefits of a disciplined daily open market stock repurchase program. ASRs can be disclosed as part of stockholders' equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 25 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653 + Details
Name: | us-gaap_AcceleratedShareRepurchasesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration